ESTRO 2025 - Abstract Book

S2292

Interdisciplinary – Health economics & health services research

ESTRO 2025

References: 1. Lievens Y, Gospodarowicz M, Grover S, Jaffray D, Rodin D, Torode J, et al. Global impact of radiotherapy in oncology: Saving one million lives by 2035. Radiother Oncol. 2017;125(2):175-7. 2. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394-424. 3. Rawla P. Epidemiology of Prostate Cancer. World J Oncol. 2019;10(2):63-89. 4. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians. 2021;71(3):209-49.

1814

Digital Poster Cost comparison of silicone-based skin care with Mepitel® versus StrataXRT®: a prospective randomised controlled trial in post-mastectomy radiotherapy Isidoro Ruisi 1,2 , Wei Wang 2,3,4 , Peter Graham 5,6,7 , Verity Ahern 2,3 , Noeline Rozanc 2 , Simon Ashworth 2 , Trevor Moodie 2 , Aysha Knowles 8 , Val Gebski 2,9 , Kirsty E Stuart 2,3,4 1 Radiation Oncology, Liverpool and Macarthur Cancer Therapy Centres, Liverpool and Campbelltown Hospitals, Sydney, Australia. 2 Radiation Oncology, Radiation Oncology Network, Western Sydney Local Health District, Sydney, Australia. 3 Sydney Medical School, C24–Westmead Hospital, The University of Sydney, Sydney, Australia. 4 Westmead Breast Cancer Institute, Westmead Hosptial, Sydney, Australia. 5 Radiation Oncology, St George Hospital, Sydney, Australia. 6 School of Clinical Medicine, University of New South Wales, Sydney, Australia. 7 Radiation Oncology, GenesisCare, Sydney, Australia. 8 Radiation Oncology, Radiation Oncology Network: Central Coast Local Health District, Gosford, Australia. 9 NHMRC Clinical Trials Centre, The University of Sydney, Sydney, Australia Purpose/Objective: Silicone-based skincare products have been shown to reduce radiation dermatitis in women undergoing post mastectomy radiotherapy (PMRT). 1-2 However, the total cost of different silicone-based skincare options is unknown. This study compares the costs of Mepitel® and StrataXRT® in PMRT, to understand the potential impact of skincare on resource allocation in radiotherapy. Material/Methods: In this multicentre prospective trial, women with breast cancer requiring PMRT (50Gy in 25 fractions) were randomised to receive Mepitel® or StrataXRT® silicon-based skincare, used during PMRT and for two weeks after PMRT, with standard creams used thereafter. The primary endpoint was total cost per patient, calculated as the sum of materials (including silicone-based skincare and dressings) and nursing time, which was converted to AUD. Each centre provided material costs per item and the levels of involved nurses to allow an averaged nursing-rate per centre. Acute toxicities were assessed using NCI CTCAE V.5.0 at baseline, weekly during PMRT and the greater of two weekly reviews after PMRT or until moist desquamation resolved, as well as at six weeks. Additional assessments were conducted as clinically required. Averages and two-tailed T-test for costs and Chi-squared statistics for toxicity were reported. Results: From September 2020 to August 2023, 60 women were randomised 1:1 (Mepitel® n=30, StrataXRT® n=30) at two public and two private centres. The average total cost per patient was 35% lower in the Mepitel® group at AUD $222.17 compared to AUD $343.04 in the StrataXRT® group (p<0.0001). The average nursing cost per patient was higher in the Mepitel® group (AUD $121.88) than the StrataXRT® group (AUD $42.74), with an average of 13.1 versus 10.7 nursing visits, respectively. However, the average material cost per patient was lower for Mepitel® (AUD $100.29) than StrataXRT® (AUD $300.30).